MedTrace Logo

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese

NCT06132841 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2026-04-03

No results posted yet for this study

Summary

A study in healthy male and female participants of non-childbearing and childbearing potential who have overweight or obesity

Conditions

  • Healthy Participants

Interventions

DRUG

AZD6234

Participants will receive repeated doses of AZD6234 as a solution via SC

DRUG

Placebo

Participants will receive matching volumes of the placebo as a solution via SC

Sponsors & Collaborators

  • Parexel

    collaborator INDUSTRY

  • AstraZeneca

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
142 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-13
Primary Completion
2026-02-03
Completion
2026-03-07
FDA Drug
Yes

Countries

  • United States
  • Japan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06132841 on ClinicalTrials.gov